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Abstract 
KRP-109 is a novel specific inhibitor of neutrophil elastase (NE).Various 
studies suggest that NE inhibitors reduce lung injury associated with systemic 
inflammatory response syndrome (SIRS). In this study, the efficacy of KRP-109 
was examined using a murine model of severe pneumonia induced by 
Streptococcus pneumoniae (S. pneumoniae). Female mice (CBA/J, aged 5 
weeks) were inoculated intranasally with penicillin-susceptible S. pneumoniae 
(ATCC49619 stain, 2.5  108CFU/mouse). KRP-109 (30 or 50 mg/kg) or 
physiological saline as a control was administered intraperitoneally every 8 h 
beginning at 8 h after inoculation, and survival rate was evaluated over 7 days. 
Histopathological and bacteriological analyses of the lung, and bronchoalveolar 
lavage were performed at 48 h post-infection. The mice treated with KRP-109 
(KRP-109 mice) tended to have higher survival rate than those given saline. The 
lung tissues of the KRP-109 mice had few neutrophils in the alveolar walls and 
less inflammation. Furthermore, KRP-109 decreased significantly total cell and 
neutrophil counts, and cytokine levels (interleukin 1β and macrophage 
inflammatory protein 2) in bronchoalveolar lavage fluid. Viable bacterial 
numbers in lung were not influenced by treatment of KRP-109. The present 
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results indicate that KRP-109 reduces lung inflammation in a murine model, and 
that KRP-109 may be useful for the treatment of patients with severe 
pneumonia. 
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1. Introduction  
Streptococcus pneumoniae (S. pneumoniae) is one of the most common 
pathogens, and causes community-acquired pneumonia that is accompanied by 
high rates of morbidity and mortality [1]. The mortality rate associated with S. 
pneumoniae pneumonia is more than 20%, despite the appropriate use of 
antibiotics and aggressive intensive care support [2]. Therapies that are currently 
being developed for treatment of this pneumonia include the development of 
effective vaccines, the strengthening of immune responses in 
immunocompromised hosts and the control of excessive inflammatory reactions. 
 Neutrophil elastase (NE) functions as a powerful physiological host defense 
against microbial pathogens in severe pneumonia. However, excessive NE can 
contribute to lung tissue damage, with effects including direct cytotoxicity to 
endothelial and epithelial cells and degradation of adhesion molecules [3]. NE 
plays an important role in the progression of acute lung injury (ALI). A specific 
neutrophil elastase inhibitor, sivelestat, has been developed in Japan [4]. This 
agent prevented subsequent progression of ALI in an animal model [5]. The 
beneficial effects of sivelestat have also been reported in several other animal 
models, including lipopolysaccharide (LPS)-induced lung inflammation and 
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ozone-induced airway response [6, 7]. We previously reported that this NE 
inhibitor was effective in mouse models of S. pneumoniae and Legionella 
pneumophila [8, 9]. In a Japanese phase III study, sivelestat was shown to be 
effective for the treatment of ALI patients [10]. Taken together, these results 
suggest that NE inhibitors may be useful for the treatment of ALI caused by 
severe pneumonia. However, satisfactory outcomes with NE inhibitors in ALI 
caused by severe pneumonia are still limited even now, and development of new 
convincing therapeutic option is still desired in the clinical practice. 
  KRP-109 (Fig. 1) is a novel specific inhibitor of NE that was discovered by 
Kyorin Pharmaceutical Co., Ltd. (Tokyo, Japan). A distinct feature of KRP-109 
is that it accumulates to a high level in lung tissue, which enables it to inhibit 
NE activity that is released from infiltrated neutrophils under inflammatory 
conditions in lung [11, 12]. The aim of this study was to evaluate the efficacy of 
KRP-109 including pharmacological profile using a murine model of severe 
pneumonia induced by S. pneumoniae. In addition to our past analysis in the 
experimental bacterial pneumonia model [8, 9], we evaluated effects of 
KRP-109 on cytokine release in lung using BALF in the presented study. 
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2. Materials and Methods 
2.1.Agents  
KRP-109 was kindly provided by Kyorin Pharmaceutical Co., Ltd. No 
antibiotic effect was observed when using KRP-109. The agent was dissolved in 
saline. 
2.2. Bacteria strains 
Penicillin-sensitive S. pneumoniae ATCC49619 was used in this study. The 
bacteria  were stored at –80C in a Microbank system (Pro-Lab Diagnostics, 
Ontario, Canada) until use. 
2.3. Laboratory animals  
  Five-week-old female CBA/J specific-pathogen-free mice (body weight, 
16-20 g) were purchased from Charles River Japan. The CBA/J mouse model of 
pneumococcal pneumonia has been described previously (2). All animals were 
housed in a pathogen-free environment and received sterile food and water in 
the Laboratory Animal Center for Biomedical Science at Nagasaki University 
(Nagasaki, Japan). The experimental protocols were approved by the Ethics 
Review Committee for Animal Experimentation at Nagasaki University. 
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2.4. Experimental murine model of pneumococcal pneumonia 
 S. pneumoniae was cultured on horse blood agar for 20 h at 37C under 5% 
CO2 and was then scraped and suspended in brain-heart infusion broth (Becton 
Dickinson, Sparks, MD) mixed with horse serum, followed by culture with 
agitation for 6 h at 37C at 250 rpm. Bacteria were then harvested by 
centrifugation (3000  g, 10 min). The organisms were resuspended in normal 
saline. The final number of bacteria was approximately 5  109 CFU/ml, as 
determined using the optical density method. Infection was induced by 
intranasal inoculation of 0.05 ml of bacterial suspension (2.5  108CFU/mouse) 
into mice under anesthesia using pentobarbital sodium (40 mg/kg 
intraperitoneally) [13]. As a non-infected control, intranasal inoculation was 
conducted with saline as the same manner. 
 2.5. Study design 
Treatment of KRP-109 was initiated at 8 h post-infection. KRP-109 (30 or 50 
mg/kg) or physiological saline was administered intraperitoneally every 8 h. 
Survival was estimated to the death of the mouse or 7 days after infection. At 
48 h post-infection, mice were anesthetized with pentobarbital and sacrificed. 
The lungs were dissected out, and were used bacteriological and 
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histopathological assays. To analysis of bronchoalveolar lavage fluid (BALF), 
bronchoalveolar lavage was performed 48 h after infection as described 
previously [14]. Briefly, bronchial cannula was inserted through the trachea 
and bronchoalveolar lavage was sequentially performed 3 times using 1 ml of 
saline each time. The recovered fluid fractions were pooled for each animal. 
 2.6. Bacteriological and histopathological analysis 
   The lungs were suspended in 1 ml of saline and the organs were 
homogenized using a homogenizer (AS One Co., Osaka, Japan). Serial 
dilutions were inoculated onto horse blood agar plates and incubated at 37C 
for 20 h. For histopathological examination, lung specimens were fixed in 10% 
buffered formalin and stained with haematoxylin-eosin. 
2.7. Analysis of bronchoalveolar lavage fluid (BALF)  
The total cell number in the BALF was determined using a hemocytometer and 
a differential cell count of 100 cells was done on slides stained with Diff-Quik 
(Sysmex Corp., Kobe, Japan). The concentrations of macrophage inflammatory 
protein 2 (MIP-2) and interleukin1β (IL-1β) in BALF were assayed using mouse 
cytokine enzyme-linked immunosorbent assay (ELISA) test kits (R&D Systems, 
Minneapolis, MN). Neutrophil elastase activity in BALF was measured using 
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the fluorogenic substrate Meo-Suc-Ala-Pro-Val-AMC [11]. Briefly, an aliquot 
(80 μl) of BALF was incubated with 20 μl of 1 mM Meo-Suc-Ala-Pro-Val AMC 
in assay buffer (2.5 M NaCl, 500 mM HEPES, pH 7.5) at 37C for 18 h. After 
incubation, the level of released AMC (7-amino-4-methyl-coumarin) was 
determined by measurement of fluorescence using an excitation wavelength of 
380 nm and an emission wavelength of 460 nm. 
 2.8. Statistical analysis 
  Data are expressed as means  standard error of the mean (SEM). Differences 
between groups were evaluated by analysis of variance. Survival analysis was 
made using the log rank test and survival rate was calculated by the 
Kaplan-Meier method. P values of <0.05 denoted the presence of a statistically 
significant difference. 
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3．Results 
3.1. Survival study 
Figure 2 shows the effect of KRP-109 treatment on survival rate of mice 
infected with S. pneumoniae over 7 days following infection. The survival rates 
for the 30 and 50 mg/kg KRP-109 treatment groups were higher than those for 
control group, but this increased survival was not significant when analyzed by 
the log rank test (P=0.12; KRP-109 50 mg/kg group versus control group). 
3.2. Bacteriological examination of the lungs  
The level of respiratory infection of inoculated mice in the KRP-109 or control 
groups was analyzed by bacteriological examination of the lungs. Respiratory 
infection, which was calculated as log10CFU/ml, occurred in all inoculated mice. 
There were no significant differences between viable bacteria numbers of the 
control group and the KRP-109 groups (control, 7.320.17 log10CFU/ml; 30 
mg/kg KRP-109, 6.860.14 log10CFU/ml; 50 mg/kg KRP-109, 6.880.15 
log10CFU/ml) (Fig. 3). 
3.3. Histopathological examination 
Light microscopy of the hematoxylin-eosin-stained lungs of the control group 
at 48 h after bacterial inoculation revealed large numbers of inflammatory cells, 
particularly neutrophils, infiltrating the alveolar spaces (Fig. 4A). In the 
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KRP-109 groups, mild inflammatory changes were evident at 30 mg/kg (Fig. 
4B). Furthermore, there was less inflammation at 50 mg/kg (Fig. 4C). 
 3.4. BALF analysis 
S. pneumoniae induced increase in total cells and neutrophils numbers in 
BALF. Numbers of total cell (Fig. 5A) and neutrophil (Fig. 5B) in BALF were 
significantly lower in the KRP-109 30 mg/kg group, and even lower in the 
KRP-109 50 mg/kg group as compared to the control group. Numbers of the 
total cell and neutrophil were decreased 54% and 52% by treatment of 50 mg/kg 
KRP-109. To examine the further effects of KRP-109, inflammatory cytokine 
levels in BALF were analyzed. The levels of IL-1β (Fig. 6A) and MIP-2 (Fig. 
6B) were detected in BALF of the control group. Decreases in these cytokine 
levels were recognized in KRP-109 30 mg/kg group, however, were not 
significant. Treatment of 50 mg/kg KRP-109 decreased significantly the levels 
of IL-1β and MIP-2 values by 46% and 24%, respectively. NE activities were 
also detected in BALF of the infected control group. The NE activities of the 
KRP-109 groups were lower than those of the control group, although these 
differences were not significant (Fig. 7). 
 




KRP-109 is a potent and competitive inhibitor of NE, with a Ki of 5.1 nM. A 
distinct feature of KRP-109 is its high accumulation in lung tissue. In a rat 
model, the highest concentration of KRP-109, with a lung tissue/plasma 
concentration ratio exceeding 20, was observed in lung among other tissues 
after intravenous administration. Furthermore, KRP-109 alleviated lung damage 
induced by human NE and LPS in rat models [11, 12]. However, there have 
been no reports which have evaluated the efficacy of KRP-109 in a severe 
pneumonia model. In the present study, we therefore evaluated the efficacy of 
KRP-109 using a murine model of severe pneumonia induced by S. 
pneumoniae.  
KRP-109-treated groups showed improved histopathological findings (Fig. 
4) and decreased the number of inflammatory cells in BALF in a 
dose-dependent manner (Fig. 5). In addition, KRP-109 treatment significantly 
decreased the levels of IL-1β and MIP-2 in BALF (Fig. 6).  
MIP-2, which is the functional homolog of the human IL-8, exhibits potent 
neutrophil chemotactic activity and may be a key mediator of neutrophil 
recruitment. In addition, it has been reported that NE induces the release of IL-8 
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from cells [15]. Furthermore, NE inhibitor has been reported to induce a 
significant reduction in serum IL-1β in rats with relevant sepsis [16]. IL-1β acts 
locally to stimulate chemotaxis and activate neutrophils in ALI and also 
stimulates the production of extracellular matrix by fibroblasts [17]. Sivelestat 
was also previously reported to significantly decrease MIP-2 levels in hamsters 
infected with S. pneumoniae [18] and in a murine model of ventilator-induced 
lung injury (VILI) [19]. Therefore, these cytokines are considered to play 
important roles in ALI.  
KRP-109 reduced NE activity in comparison with the control group, although 
this reduction was not statistically significant (Fig. 7).In addition, KRP-109 
improved survival rates in a dose-dependent manner, but this increased survival 
was not statistically significant (Fig. 2). Although KRP-109 is a potent inhibitor 
of human NE (IC50=7 nM, Ki of 5.1 nM) [11], KRP-109 shows species 
differences for inhibition of neutrophil elastase with mouse IC50 of 274 nM 
(in-house data by Kyorin). These marginal effects of KRP-109 on NE activity 
and the mouse survival rate may be due to species difference of neutrophil 
elastase inhibition.  
Also, continuous infusion of KRP-109 has been shown to decrease NE 
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activity in a bleomycin-induced lung injury model [20]. Therefore, the marginal 
effectivity of KRP-109 in this study may be due to the difference in drug 
administration. Even so, inhibitory effect on inflammatory changes in 
pulmonary histopathology finding was observed; therefore, we rather consider 
inhibition of initial neutrophils infiltration into lung and consequent lung 
damage, which should have been caused by elastase inhibition by KRP-109, led 
to subsequent reduction of neutrophil counts in BALF and inhibition of 
inflammatory histopathology changes of lung in the present study. 
On the other hand, NE is a key molecule of the innate immune system and is 
required for effective killing of phagocytosed bacterial and fungal pathogens [21, 
22]. Our results, however, did not show any significant differences between the 
level of respiratory infection in the control and the KRP-109-treated groups 
following bacteriological examination (Fig. 3). This result indicates that NE 
inhibitors do not aggravate infection. 
Interestingly, Ishiyama et al. reported KRP-109 alleviated lung damage 
induced by human NE and LPS in rat models [11, 12]. Its effects consisted of 
inhibition of lung edema and lung hemorrhage. Furthermore, it was reported 
KRP-109 decreased TGF-β related genes expression and TGF-β1 release 
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induced by human NE in rat [20]. Based on present study and previous studies 
on KRP-109 to date, it is considered that KRP-109 demonstrates 
anti-inflammatory pharmacological effects, all of which are considered to occur 
in the inflammation site of lung tissue, in ALI experimental conditions probably 
contributed by its distinctive characteristics, i.e., high distribution in lung 
together with specific inhibitory activity of human NE, and that KRP-109 
possesses potential effects on ALI consequent to severe pneumonia. Future 
studies should investigate the serum and tissue concentration of KRP-109 and 
the efficacy of KRP-109 in combination with antibiotics in a model of severe 
pneumonia.  In conclusion, KRP-109 improved lung inflammation in a murine 
model of severe pneumococcal pneumonia. The present results suggest that 
KRP-109 may be useful for the treatment of patients with severe pneumonia. 
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Fig. 1. Chemical structure of KRP-109. 





Fig. 2. Survival study of mice with pneumococcal pneumonia after treatment 
with KRP-109. Ten mice in each group were treated with KRP-109 at a dose of 
30 mg/kg (filled triangles) or 50 mg/kg (filled circles), or were treated with 
saline (filled squares). Survival was then estimated at the indicated times and the 
results are displayed as a Kaplan-Meier plot. The survival rates of KRP-109 
groups were higher than that of control, but the increase in survival rate was not 
significant as assessed using the log rank test (P=0.12; KRP-109 50 mg/kg 
group versus control group). 





Fig. 3. Effect of KRP-109 on the number of viable bacteria in the lungs of mice. 
Mice were inoculated with 2.5  108 CFU of S. pneumoniae. Treatment with 
KRP-109 did not affect the number of viable bacteria in comparison with 
control (n=5 in each group).  





Fig. 4. Histochemical analysis of the lungs of infected mice following KRP-109 
treatment. High-power magnification (100; hematoxylin and eosin) of the lung 
at 48 h post-infection. Photomicrographs exist lung tissues of control group (A),  
KRP-109 30 mg/kg group (B) and KRP-109 50 mg/kg group (C). KRP-109 
treatment, especially at a dose of 50 mg/kg, inhibited lung inflammation due to 
infection(n=5 in each group).  




Fig. 5. Effect of KRP-109 on number of inflammatory cells in BALF of infected 
mice. Numbers of total cells (A) and neutrophils (B) in BALF were compared 
with control group and KRP-109 group (30 or 50 mg/kg). The total cell numbers 
were determined using a hemocytometer with Turk stain and neutrophil 
numbers were done on slides stained with Diff-Quik. The data are expressed as 
means  SEM. *, P<0.05, **, P<0.01 versus control group (n=8 in each group). 




Fig. 6. Effect of KRP-109 on inflammatory cytokines in BALF of infected mice. 
The cytokine levels in BALF on control and KRP-109 groups (30 and 50 
mg/kg) were detected using ELISAs: IL-1β (A) and MIP-2 (B). The data are 
expressed as means  SEM. *, P<0.05, **, P<0.01 versus control group (n=8 in 
each group). 





Fig. 7. Effect of KRP-109 on NE activity in BALF. NE activity in BALF was 
measured using the fluorogenic substrate Meo-Suc-Ala-Pro-Val-AMC (AMC). 
KRP-109 reduced NE activity in comparison with the control group, but this 
difference was not statistically significant (n=5 in each group). 
